Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

DSGN 11.13.2024

Full Press ReleaseSEC FilingsOur DSGN Tweets

About Gravity Analytica

Recent News

  • 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.19.2024 - 2024 Jefferies London Healthcare Conference
  • 11.13.2024 - Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:

2024 Jefferies London Healthcare ConferencePresentation:Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation:London, UK

Piper Sandler 36thAnnual Healthcare ConferenceFireside Chat:Tuesday, December 3, 2024, at 11:30 a.m. ETLocation:New York, NY

Live webcasts of the presentations will be availablehereand in the investors section of the company’s website atwww.designtx.com. The webcasts will be archived for at least 30 days following each presentation.

About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTACTM gene targeted chimera small molecules. The company’s GeneTACTM molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTACTM small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:Renee LeckTHRUST Strategic Communicationsrenee@thrustsc.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com